GHK-Cu Peptide Injection Dosage and Frequency: What the Research Actually Supports

There is no established GHK-Cu peptide injection dosage or frequency for humans, because no published clinical trial has tested injected GHK-Cu in people. Every dose and schedule you see online is therefore extrapolated from animal work, from topical cosmetic use, or from guesswork. A 2026 orthopaedic review in the American Journal of Sports Medicine put it plainly when it said that, for the injectable peptides it covered, including GHK-Cu, information about dosing, frequency and duration "remains unknown."

That is an unsatisfying answer if you came here looking for a number, but it is the accurate one. This article explains what GHK-Cu is, what doses and schedules researchers have actually used in animals, why those figures do not translate into a human protocol, and what the most recent reviews say about the evidence. It is educational content about published research, not medical advice, and like most peptides discussed on this site, GHK-Cu is not an FDA approved drug.

GHK-Cu is a small peptide made of three amino acids (glycine, histidine and lysine) bound to a copper ion. The peptide part, GHK, is made by your body and circulates in your blood. According to a 2012 review by Loren Pickart, who first described the molecule (Oxidative Medicine and Cellular Longevity, 2012, doi.org/10.1155/2012/324832), GHK was discovered in 1973 as an activity in human albumin, and it "easily forms a copper complex or GHK-Cu" because of its high affinity for copper.

So, is GHK-Cu a peptide? Yes, it is a tripeptide and one of the smallest bioactive peptides studied, and the copper ion is what most of its proposed biology depends on. For a broader look at its skin, hair and wound research, see our guide GHK-Cu (Copper Peptide): Skin, Hair, and Healing Benefits Explained.

GHK plasma levels fall as you age. In a 2018 review, Pickart and Margolina report that the plasma level of GHK is about 200 ng/mL at age 20 and declines to 80 ng/mL by age 60 (International Journal of Molecular Sciences, 2018, doi.org/10.3390/ijms19071987). This age decline is the main reason GHK-Cu is marketed as an antiaging peptide, although it is worth knowing that both of these reviews come from the molecule's discoverer, whose listed affiliation on the 2012 paper is the skin care company Skin Biology.

An independent group measured plasma GHK in a small clinical comparison. In a 2023 study by Deng and colleagues (Journal of Cachexia, Sarcopenia and Muscle, doi.org/10.1002/jcsm.13213), plasma GHK was 70.27 ng/mL in 9 people with chronic obstructive pulmonary disease (COPD) versus 133.0 ng/mL in 11 healthy controls of similar age, and lower GHK tracked with smaller chest muscle area in the COPD group. That finding is an association in a small sample, and it is not evidence that injecting GHK-Cu restores muscle in people.

A GHK-Cu injection is the copper peptide given under the skin or into tissue instead of being applied as a cream or serum. Most of the human data on GHK-Cu come from topical cosmetic products, while injectable GHK-Cu is sold mainly as a research chemical or through some compounding channels and has not been through the clinical trials that set doses for approved peptide drugs.

A 2026 review by Luansritisakul and colleagues in Current Pain and Headache Reports (doi.org/10.1007/s11916-026-01542-z), which covered GHK-Cu alongside BPC-157, TB-500 and other regenerative peptides, noted that most of these therapies "remain unapproved by the U.S. Food and Drug Administration (FDA)" and that clinical evidence in humans is limited.

If you want background on how absorption differs between abdomen, thigh and arm injections for peptides in general, our article Does Injection Site Change How a Peptide Absorbs? covers the research on approved drugs.

No human study defines a GHK-Cu injection dosage. The 2026 American Journal of Sports Medicine primer by Mayfield and colleagues at the Keck School of Medicine (doi.org/10.1177/03635465251357593) reviewed the most popular injectable peptides and concluded that GHK-Cu showed promise in wound healing and in reducing inflammation, but that "no clinical data support its use for musculoskeletal conditions." The same review states that indications, dosing, frequency and duration remain unknown for these peptides as a group.

The doses that do exist in the literature come from animal experiments, and they were chosen to test a biological question in a specific model rather than to find a safe or effective human amount.

The table below lists the GHK-Cu doses and schedules reported in the animal studies verified for this article.

Two things stand out in that table. The doses are expressed per kilogram of a mouse or per millilitre of injected solution, and neither unit converts cleanly into a human dose. Each study also used a different route and a different target tissue, so together they do not point toward one consistent amount.

There is no evidence based GHK-Cu injection frequency for people. The only animal study in this set with a clearly defined repeating schedule gave injections once a week: in that rat study by Fu and colleagues (Journal of Orthopaedic Research, 2015, doi.org/10.1002/jor.22831), 72 animals had ACL reconstruction and were randomized to saline, 0.3 mg/ml GHK-Cu or 3 mg/ml GHK-Cu (n = 24 per group), with knee injections given once a week for 4 weeks starting in week 2.

The result is a useful warning about frequency and duration. At 6 weeks, both GHK-Cu groups had a smaller side to side difference in knee laxity than saline, and the 0.3 mg/ml group had a stiffer graft, but by 12 weeks the differences were gone. The authors concluded that "the beneficial effects could not last as treatment discontinued," which suggests the effect was tied to ongoing exposure, and the study gives no information on what longer or more frequent dosing would do.

GHK is a very small peptide, and small peptides are cut apart quickly by enzymes in blood and tissue. In a 1997 rat study by Endo and colleagues that developed a method to measure GHK in plasma (Journal of Chromatography B, doi.org/10.1016/s0378-4347(96)00460-4), researchers gave a single intravenous dose and found that "GHK was rapidly degraded to HK, which was eliminated rapidly." HK is the two amino acid fragment left after the glycine is removed.

That fast breakdown matters if you are thinking about frequency, because a peptide that disappears quickly from circulation would, in theory, need repeated dosing to maintain any systemic effect. However, no human pharmacokinetic study of injected GHK-Cu has measured its half life, peak level or duration of action, so the right interval is simply not known. Our explainer Peptide Half Life Explained: Why Some Peptides Are Dosed Daily and Others Weekly shows how this works for peptides that have been measured in people.

Animal doses cannot be converted into a reliable human GHK-Cu dose because the studies were not designed to find one. Each experiment tested whether GHK-Cu changed a specific outcome in a specific injury model, and none measured the blood levels needed for an effect, the dose at which side effects start, or how the peptide behaves after repeated injection in people.

There is also a chemistry problem. A 2026 systematic evidence map by Mateescu and colleagues in Pharmaceutics (doi.org/10.3390/pharmaceutics18091077), which searched the literature through 12 August 2026, argued that much of the research treats GHK-Cu as a single active ingredient even though its copper binding, stability, pharmacokinetics and toxicity vary with how it is formulated. Put simply, two vials both labelled GHK-Cu may not contain the same ratio of peptide to copper or the same amount of free copper, which makes it hard to compare doses even between studies, let alone between a lab study and a product bought online.

The human evidence on GHK-Cu is sparse and comes almost entirely from topical use. The 2026 Pharmaceutics review found that the clinical evidence "remains sparse" and does not meet current quality standards for defining the active substance, and it identified only small cosmetic studies and one ongoing trial.

The laser resurfacing study by Miller and colleagues (Archives of Facial Plastic Surgery, 2006, doi.org/10.1001/archfaci.8.4.252) is the clearest example. Patients were randomized to skin regimens with or without GHK-Cu, and blinded evaluators and computer analysis found no significant differences in redness or wrinkles, although patients using GHK-Cu reported higher satisfaction. None of the human studies tested an injected dose. If skin is your main interest, the topical evidence is discussed in more depth in our comparison GHK-Cu vs Retinol: The Peptide Your Skin Already Knows.

Animal studies found consistent signs of tissue repair activity, which is why interest in GHK-Cu continues. In the smoke exposed mouse study by Deng and colleagues, GHK-Cu at 0.2 and 2 mg/kg improved grip strength from 175.5 g in untreated smoke exposed mice to 257.6 g and 339.1 g, and it reduced muscle loss. In the earlier rat wound chamber model by Maquart and colleagues (Journal of Clinical Investigation, 1993, doi.org/10.1172/JCI116842), injected GHK-Cu produced a concentration dependent increase in collagen, DNA, protein and glycosaminoglycans.

These results support biological plausibility, but they do not show that the same effect happens in people, at what dose it would happen, or what risks would come with it.

The safety of injected GHK-Cu in humans has not been established in clinical trials. The 2026 Pharmaceutics review lists safety thresholds for each route of administration and control of free (labile) copper among the requirements still unmet before GHK-Cu could be developed as a medicine, and the 2026 Current Pain and Headache Reports review advised that use of these largely unapproved peptides "should be guided by careful clinical judgment."

The practical gaps that matter for your safety include product purity, the actual copper content of a vial, the sterility of research grade products, and the absence of human data on repeated injections. If you are considering GHK-Cu, discuss it with a licensed clinician who can review your health history and any copper related conditions.

The honest answer to the question of GHK-Cu peptide injection dosage and frequency is that research has not produced one. The animal studies used doses such as 0.2 and 2 mg/kg in mice and weekly knee injections of 0.3 or 3 mg/ml in rats, the benefit in the rat study faded once injections stopped, and GHK itself breaks down quickly after an intravenous dose. The 2026 Pharmaceutics review summed up the field by saying GHK-Cu "should be regarded as a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug."

If you see a confident dosing chart for injectable GHK-Cu, it is worth asking where the numbers came from, because they did not come from human trials. Topical GHK-Cu has a longer record of use in skin care, and the injectable form is best understood as an open research question for now.

Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative Medicine and Cellular Longevity, 2012, doi.org/10.1155/2012/324832.

Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018, doi.org/10.3390/ijms19071987.

Deng M and colleagues. GHK-Cu rescues cigarette smoking induced skeletal muscle dysfunction via a sirtuin 1 dependent pathway. Journal of Cachexia, Sarcopenia and Muscle, 2023, doi.org/10.1002/jcsm.13213.

Mayfield CK and colleagues. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026, doi.org/10.1177/03635465251357593.

Mateescu DM and colleagues. GHK-Cu as a Bioactive Metallopeptide and Drug Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics, 2026, doi.org/10.3390/pharmaceutics18091077.

Fu SC and colleagues. Tripeptide copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. Journal of Orthopaedic Research, 2015, doi.org/10.1002/jor.22831.

Endo T, Miyagi M, Ujiie A. Simultaneous determination of GHK and its metabolite HK in rat plasma by high performance liquid chromatography with post column derivatization. Journal of Chromatography B, 1997, doi.org/10.1016/s0378-4347(96)00460-4.

Maquart FX and colleagues. In vivo stimulation of connective tissue accumulation by the tripeptide copper complex GHK-Cu in rat experimental wounds. Journal of Clinical Investigation, 1993, doi.org/10.1172/JCI116842.

Miller TR and colleagues. Effects of topical copper tripeptide complex on CO2 laser resurfaced skin. Archives of Facial Plastic Surgery, 2006, doi.org/10.1001/archfaci.8.4.252.

Luansritisakul C and colleagues. Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. Current Pain and Headache Reports, 2026, doi.org/10.1007/s11916-026-01542-z.